━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
TECHNOLOGY TRANSFER PACKAGE
P-25
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

**TECHNICAL READINESS**: T1-FAIL
**TRANSFER POSTURE**: CO_DEVELOPMENT_REQUIRED
**COMMERCIAL STATE**: UNCONTACTED
**VALIDATION**: VALID

**ONE-LINE BUYER TRUTH**
A P-25 mechanism whose current model fails the target but may survive with additional repair work.

**EXECUTIVE PROPOSITION**
Technology: Self-referencing piezoresistive pressure sensor. Dual-element differential measurement cancels common-mode drift.. Problem: Implantable pressure sensor drift over 30+ day implantation. Common-mode drift cancelable. Non-common-mode drift (biofouling, asymmetric creep) not ca.

**BUYER PROBLEM**
Who: Sensor OEM (Codman, Medtronic, Raumedic)
Problem: Implantable pressure sensor drift over 30+ day implantation. Common-mode drift cancelable. Non-common-mode drift (biofouling, asymmetric creep) not cancelable by simple self-referencing.
Current solution: Periodic recalibration protocol (existing clinical practice) — inconvenient but reliable

**TECHNOLOGY**
Self-referencing piezoresistive pressure sensor. Dual-element differential measurement cancels common-mode drift.

**EVIDENCE LEDGER** (structured atoms — no blending)
  MODELLED:
    - claim: 67.8% drift cancellation (MODELED)
      scope: internal computational model
      limitation: model prediction — not experimentally verified
    - claim: 3.45 mmHg error over 30 days (MODELED)
      scope: internal computational model
      limitation: model prediction — not experimentally verified
  ASSUMED:
    - claim: FAILED ASSUMPTION: Falsification threshold (2.0 mmHg) NOT met — 3.45 mmHg error
      scope: hostile attack or model test
      limitation: this assumption broke — buyer must not rely on it
    - claim: FAILED ASSUMPTION: Biofouling dominates non-common-mode drift
      scope: hostile attack or model test
      limitation: this assumption broke — buyer must not rely on it
    - claim: FAILED ASSUMPTION: Self-referencing alone insufficient for absolute pressure measurement
      scope: hostile attack or model test
      limitation: this assumption broke — buyer must not rely on it

**STRONGEST ALTERNATIVE**
Periodic recalibration protocol (existing clinical practice) — inconvenient but reliable

**KNOWN FAILURES**
  - Falsification threshold (2.0 mmHg) NOT met — 3.45 mmHg error
  - Biofouling dominates non-common-mode drift
  - Self-referencing alone insufficient for absolute pressure measurement

**REMAINING UNCERTAINTY**
Whether anti-fouling coating or periodic recalibration can bring error below 2.0 mmHg. If not, mechanism is falsified for absolute measurement (may survive for trending only).

**DECISIVE EXPERIMENT**
  Experiment: Bench test: dual-element sensor with anti-fouling coating vs uncoated, 30-day soak in mock CSF, measure drift.
  Pass: Coated sensor error < 2.0 mmHg over 30 days (95% CI below threshold)
  Fail: Coated sensor error > 2.0 mmHg over 30 days
  Cost: $8,000 (ESTIMATED)
  Timeline: 12 weeks (ESTIMATED — 30-day soak + analysis)

**REGULATORY STATUS**
Class II (510(k)) if used for trending. Class III (PMA) if used for absolute ICP measurement.

**COMMERCIAL ROUTE**
License to sensor OEM IF anti-fouling repair works. Otherwise: cemetery.

**IP / DILIGENCE STATUS**
  BUYER_DILIGENCE_REQUIRED — no patent search performed
  Full freedom-to-operate analysis by buyer counsel
  (We are not running a patent court.)

**BUYER'S NEXT ACTION**
Commission $8K coated-sensor bench test OR reject (mechanism may be falsified)
  BUYER_ACTION_ID: BA-P25-001

**VALIDATION RESULTS** (computed by independent validator, not generator)
  Q1 (send without verbal): PASS
  Q2 (identify next step): PASS
  Q3 (facts vs hypotheses): PASS
  Q4 (challenge without trusting): PASS
  Errors: NONE

━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━